Cardiac rehabilitation for people with chronic stable angina

ISRCTN ISRCTN10054455
DOI https://doi.org/10.1186/ISRCTN10054455
IRAS number 300485
Secondary identifying numbers CPMS 50446
Submission date
15/09/2021
Registration date
16/09/2021
Last edited
28/08/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Angina is chest pain caused by a build-up of fats and cholesterol in the walls (atherosclerosis) of the blood vessels that supply the heart (coronary arteries), which restricts blood flow to the heart muscle, especially during exercise. Current management of angina consists of behaviour change, drug treatment and operations to improve blood flow to the heart (revascularization).

Cardiac rehabilitation is routinely offered to patients following a heart attack or revascularisation procedures, but not for chronic, stable angina. Cardiac rehabilitation consists of lifestyle change, exercise training, education and mental health interventions. The National Institute for Health and Care Excellence will not support cardiac rehabilitation for chronic stable angina until stronger evidence of effectiveness and cost-effectiveness is available.

The aims of the project are to improve the health of people with long-term angina chest pain, which is not getting worse and does not require an operation but still limits daily activities. We aim to assess whether a rehabilitation programme is more effective than usual care in improving the health of people with long-standing stable angina, whether the programme is good value for money, and whether it is delivered as intended. The programme uses behaviour change techniques such as goal-setting, self-monitoring, providing feedback on behaviour, graded tasks, social reward, providing information about health consequences and reducing negative emotions.

Who can participate?
Patients with chronic stable angina aged 18 years and older from four regions: Liverpool, Lancashire, Leicester and North Wales, which are all areas of high disease burden with socio-economic deprivation. Some of these areas include high proportions of BAME groups (Leicester, East Lancashire) and areas with low research activity in this field (Blackpool, North Wales).

What does the study involve?
Participants will be split into two groups randomly. by a computer. Group A will receive usual care from their GP plus a cardiac rehabilitation programme called ‘Activate Your Heart’. Group B will receive usual care from their GP. ‘Activate Your Heart’ is an interactive website for participants to use at home. It is secure and protected by a password. The programme was developed by a team of health care professionals, people with angina and software designers. The programme includes education, promoting a healthy diet and physical activity, reducing risk factors for heart attack and improving mental wellbeing. The programme helps participants to set goals, monitor progress and gives feedback on how they are doing. It encourages participants to gradually increase their activity levels. A paper manual will be available for participants who are unable to use the online version or for those who feel they would prefer a paper version. We would also like participants to complete some questionnaires whilst taking part in the study and also wear a small device called an ActivPAL device which looks out how active participants are.

What are the possible benefits and risks of participating?
The risks of the online rehabilitation intervention ‘Activate Your Heart’ are minimal. There may be a small risk of injury or provoking an episode of angina when exercising, but to prevent this, the physical activity goals are carefully set. Participants can contact the cardiac rehabilitation therapists for advice and support via an online email link or by joining an online scheduled weekly chat room, participants will also be given a phone number to contact them on. Experience from using the ‘Activate Your Heart’ programme for cardiac rehabilitation has shown that it is very safe.

Where is the study run from?
The University of Liverpool (UK)

When is the study starting and how long is it expected to run for?
From August 2021 to August 2024

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Farhiya Ashoor
activate.trial@liverpool.ac.uk

Study website

Contact information

Prof Nefyn Williams
Scientific

University of Liverpool
Department of Primary Care and Mental Health
1st Floor Block B Waterhouse Building
Brownlow Street
Liverpool
L69 3GL
United Kingdom

ORCiD logoORCID ID 0000-0002-8078-409X
Phone +44 (0)151 795 5305
Email Nefyn.Williams@liverpool.ac.uk
Mr Ben Hardwick
Scientific

Liverpool Clinical Trials Centre
University of Liverpool
2nd Floor, Institute in the Park
Alder Hey Children’s NHS Foundation Trust
Eaton Road
Liverpool
L12 2AP
United Kingdom

ORCiD logoORCID ID 0000-0003-1050-5777
Phone +44 (0)151 794 9773
Email b.hardwick1@liverpool.ac.uk
Prof Sally Singh
Scientific

University Hospitals of Leicester NHS Trust
Biomedical Research Centre – Respiratory
Glenfield Hospital
Groby Road
Leicester
LE3 9QP
United Kingdom

ORCiD logoORCID ID 0000-0002-9834-0366
Phone +44 (0)116 2502535
Email sally.singh@uhl-tr.nhs.uk
Ms Farhiya Ashoor
Scientific

Liverpool Clinical Trials Centre
University of Liverpool
2nd Floor, Institute in the Park
Alder Hey Children’s NHS Foundation Trust
Eaton Road
Liverpool
L12 2AP
United Kingdom

ORCiD logoORCID ID 0000-0001-8315-8126
Phone +44 (0)151 795 8761
Email fashoor@liverpool.ac.uk

Study information

Study designRandomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleCardiac rehabilitation for people with chronic stable angina (ACTIVATE): a randomised controlled trial
Study acronymACTIVATE
Study hypothesisCan a rehabilitation programme combined with usual heart care be better than usual heart care alone in improving the health of people with long-standing stable angina?
Ethics approval(s)Approved 23/09/2021, North of Scotland Research Ethics Service (Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE; +44 (0)1224 558458; gram.nosres@nhs.scot), ref: 21/NS/0116
ConditionAngina pectoris
InterventionPeople with long-term stable angina will be recruited and divided into two groups. One group will receive usual care; the other group will undertake a rehabilitation programme in addition to usual care. Participants in undertaking the rehabilitation programme will be given access to ‘ActivateYourHeart’ (www.activateyourheart.org.uk). The programme is tailored to individual needs and is in four stages, which can be completed in 8 weeks, but access to the site and its features continue for 12 months. Participants will complete the intervention with support from cardiac rehabilitation staff. The online programme called ‘ActivateYourHeart’ has already been developed. It was designed to be used by many kinds of people with heart disease including those who cannot or do not want to attend group rehabilitation sessions. It can be used at home and can be completed at the participant’s own pace. An early preliminary study on people with stable angina indicates that it may be beneficial and that a larger trial is needed. People usually access this programme using their computer or their mobile device and the programme provides them with a tailored plan. However, before beginning the programme each participant receives face-to-face training using the website and a written user manual. A paper-based version will also be available if people are not comfortable using the website.

Before the start of the programme, participants will review the participant information sheet and provide written informed consent at their GP surgery and questionnaires will be used to measure physical limitations, the frequency and severity of chest pain, shortness of breath, quality of life, anxiety, depression, and the use of health services. Participants will complete assessment questionnaires at baseline, 6, and 12 months either via phone or in their GP surgery. Additionally, physical activity will be measured with the ActivPAL accelerometer device, which participants will collect from their GP surgery and take home with them to be worn continually for 7 days at each assessment point, and return to their GP surgery after 7 days. The Incremental Shuttle Walk Test will be completed at the participant's GP surgery under the supervision and guidance of the research staff. As well as comparing the effectiveness of the rehabilitation programme between the two groups, the study will also assess its value for money, and whether the rehabilitation was delivered as intended.
Intervention typeBehavioural
Primary outcome measurePhysical limitations measured using the UK Version of Seattle Angina Questionnaire (SAQ-7) Physical Limitation domain at baseline, 6, and 12 months
Secondary outcome measures1. Dyspnea measured using the Rose Dyspnea Scale at baseline, 6, and 12 months
2. Anxiety and depression measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, 6, and 12 months
3. Perceived self-efficacy measured using the Generalised Self-Efficacy scale at baseline, 6, and 12 months
4. Physical activity measured with the ActivPAL accelerometer over 7 days at baseline, 6, and 12 months
5. Health–related physical activity measured using the International Physical Activity Questionnaire (IPAQ) at baseline, 6, and 12 months
6. Exercise capacity measured using the Incremental Shuttle Walk Test at baseline, 6, and 12 months
7. Quality of life measured using the EuroQol 5-Dimension 5-Level Quality of Life questionnaire (EQ-5D-5L) at baseline, 6, and 12 months
8. Service utilisation measured using the Client Service Receipt Inventory (CSRI) at baseline, 6, and 12 months
Overall study start date01/08/2021
Overall study end date01/08/2024

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 518; UK Sample Size: 518
Participant inclusion criteria1. Aged ≥18 years
2. Chronic stable angina with at least 2 out of 3 of the following features:
2.1. Constricting central chest pain
2.2. Precipitated by exertion or emotional stress
2.3. Relieved by rest or glyceryl trinitrate spray
3. Documented coronary artery disease on angiography with ≥70% stenosis of coronary arteries based on invasive coronary angiography, computerised tomography angiography, or reversible myocardial ischaemia on myocardial perfusion testing
4. Revascularisation procedures not planned and treated with medical treatments only. Including people with previous MI, or previous revascularisation procedure who may have attended cardiac rehabilitation in the past.
Participant exclusion criteria1. History of myocardial infarction (MI) within the last 12 months on electronic health record search
2. History of revascularisation procedure within the last 12 months, or planned at the time of study consent
3. Participation in cardiac rehabilitation programme within the last 12 months, or planned at time of study recruitment
4. Significant co-morbidities (as deemed by person confirming eligibility) that would limit participation in the exercise based rehabilitation programme
5. Refractory angina on maximal medical therapy
Recruitment start date01/12/2021
Recruitment end date01/02/2023

Locations

Countries of recruitment

  • England
  • United Kingdom
  • Wales

Study participating centres

Clarence Medical Centre
West Kinmel Street
Rhyl
Denbighshire
LL18 1DA
United Kingdom
Plas Menai Surgery
Penmaenmawr Road
Llanfairfechan
Conwy
LL33 0PE
United Kingdom
Corwen Health Centre
Green Lane
Corwen
Denbighshire
LL21 0DN
United Kingdom
Healthy Prestatyn
Rhuddlan Iach Ty Nant
Nant Hall Road
Prestatyn
Denbighshire
LL19 9LN
United Kingdom
Marshalls Cross Medical Centre
St Helens Hospital
Marshalls Cross Road
St Helens
Merseyside
WA9 3DA
United Kingdom
Vauxhall Health Centre
Limekiln Lane
Vauxhall
Liverpool
L5 8XR
United Kingdom
Fishergate Hill Surgery
50 Fishergate Hill
Preston
Lancashire
PR1 8DN
United Kingdom
Lancaster Medical Practice
8 Dalton Square
Lancaster
Lancashire
LA1 1PN
United Kingdom

Sponsor information

University of Liverpool
University/education

Clinical Directorate
2nd Floor Block C Waterhouse Building
3 Brownlow St
Liverpool
L69 3GL
England
United Kingdom

Phone +44 (0)151 794 8373
Email sponsor@liverpool.ac.uk
Website http://www.liv.ac.uk/
ROR logo "ROR" https://ror.org/04xs57h96

Funders

Funder type

Government

National Institute for Health Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date30/09/2026
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryStored in non-publicly available repository, Available on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planCurrent IPD sharing plan as of 15/02/2024:
The datasets generated and analysed during this study will be stored in a non-publicly available repository. These datasets will be available upon request from 31/07/2026. For access to these datasets, please contact Prof. Nefyn H Williams (nefyn.williams@liverpool.ac.uk). Consent was required and obtained from all participants. Data will be anonymised before it is shared. There are no ethical or legal restrictions.

Previous IPD sharing plan:
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No
Protocol article 25/03/2024 27/03/2024 Yes No

Editorial Notes

28/08/2024: The intention to publish date was changed from 01/09/2024 to 30/09/2026.
27/03/2024: Publication reference added.
15/02/2024: IPD sharing plan updated.
31/05/2022: Ethics approval details.
24/05/2022: Ethics approval details and IPD sharing statement added.
15/09/2021: Trial’s existence confirmed by the National Institute for Health Research (NIHR).